SOURCE BioDelivery Sciences International, Inc.
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
Two are turnaround stories, and two are oversold.
Flexion Therapeutics and BioDelivery Sciences are well below what they once fetched.
These stocks will be great stories in the second half of 2017, and are significantly undervalued.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.